Bringing the fundamentals into focus…
Back to Telix Pharmaceuticals Limited
How Telix Pharmaceuticals Limited stacks up
TLX · against 1,336 other Healthcare companies
Valuation
31/ 100
Below the middle of the pack.
Ranked #917 of 1,337 · scores higher than 31% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 30–39, including TLX · Click a bar to see the companies
Why valuation scores 31?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 61% of peers. EBITDA yield: 0.8% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -0.1% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -0.7% vs peer median 0.0%
Metric by metric
Position: dot = TLX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TLX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 1.1% | 1.5% | 47% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 2.1% | 4.2% | 39% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | Not reported | -1.0% | — | — | 20% |
| Book yieldHigher is better · 1,306 reported | 15.9% | 37.9% | 22% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around TLXScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score